Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma

Cancer Immunology Immunotherapy

Volumn 44, Issue 3, 1997, Pages 137-149

  Kirkwood, John M ^b,c   Wilson, John ^b   Whiteside, Theresa L ^a   Donnelly, Sandra ^d   Herberman, Ronald B ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d NONE

Author keywords

Cancer; Immunomodulator; Immunostimulants; Melanoma; OK 432; Picibanil (OK 432)

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CYTOKINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GALLIUM 67; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; PICIBANIL; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INTRADERMAL DRUG ADMINISTRATION; MALE; MELANOMA; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; MALE; MELANOMA; PICIBANIL;

EID: 0030912706     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050366     Document Type: Article

References (17)

1. Balch CM, Smalley RV, Bartolucci AA, Burns D, Presant CA, Durant JR, Southeastern Cancer Study Group (1982) A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer 49:1079
2. Begg C, Kalish L (1985) Treatment allocation in clinical trials: a review. Statist Med 129
3. Cascinelli N, Rümke P, MacKie R, Morabito A, Bufalino R (1989) The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol Immunother 28:282
4. Coley WB (1893) The Treatment of malignant tumors by repeated inoculations of erysipelas: with a report of 10 original cases. American Journal on Medical Science 105:487-511
5. Hersey P, Edwards A, McCarthy WH (1980) Tumor-related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patients. Int J Cancer 25:187
6. Hersey P, Murray E, Grace J, McCarthy WH (1985) Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma. Pathology 17:385
7. Hoshino T, Uchida A (1984) OK-432 (picibanil): property, action and clinical effectiveness: In: Hoshino T, Uchida A (eds) Clinical and experimental studies in immunotherapy. (Proceedings of an International Congress of Chemotherapy, Vienna, September 1983) Excerpta Medica, Amsterdam, p1
8. Ishida N, Hoshino T (1985) Streptococcal preparation as a potent biological response modifier. Excerpta Medica, Japan, p1
9. Kirkwood JM (1995) Biologic therapy with interferon α and β: clinical applications - melanoma: In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer: principles and practice. Lippincott, Philadelphia, p388
10. Kirkwood JM, Wilson J, Whiteside T, Bryant J, Vlock D, Straw L, Herberman R (1992) Antitumor and immunomodulatory effects of intradermal picibanil (OK-432): results of a phase IA trial and status of a phase IB trial in high-risk melanoma (abstract). Cancer Invest 10 [Suppl 1]:20
11. Lotze MT (1995) Biologic therapy with interleukin-2: preclinical studies: In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer: principles and practice. Lippincott, Philadelphia, p207
12. Lotze MT, Zeh III, Elder EM, Cai Q, Pippin BA, Rosenstein MM, Whiteside TL, Herberman R (1992) Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma. J Immunother 12:212
13. Morrison RS (1991) Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes. J Biol Chem 266:728
14. Morton DL, Malmgren RA, Holmeso EC, Ketcham AS (1968) Demonstration of antibodies against human malignant melanomaby immunofluorescence. Surgery 64:233
15. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS (1981) Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1:51
16. Talmadge JE (1983) Interim report on OK-432 (Picibanil). Report to decision network committee of BRMP of NCI
17. Zelen M (1974) The randomization and stratification of patients to clinical trials. J Chronic Dis 27:365